Πέμπτη 1 Ιουνίου 2017

Indoximod Combo Triggers Responses in Melanoma [News in Brief]

Adding the investigational IDO-pathway inhibitor indoximod to checkpoint inhibitor therapy resulted in a 52% overall response rate in patients with advanced melanoma enrolled in a phase II trial. The combination strategy has potential as an alternative for patients whose tumors do not respond to standard therapy.



from Cancer via ola Kala on Inoreader http://ift.tt/2ri2P4k
via IFTTT

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου